# A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.

> **NCT01195272** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 21 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT01195272
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2014-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01195272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01195272, "A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01195272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*